Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Daxor Corporation DXR

Healthcare  —  Medical Instruments & Supplies
11.01 (0.38) (3.34%) as of 25 Sep
Market cap
$66.5M
P/E
5.1×
Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Daxor Corporation (DXR) Business Profile

Updated before January 2025

Company Overview

Daxor Corporation (DXR) is a pioneering medical instrumentation and biotechnology company specializing in blood volume analysis technology. Founded in 1970, the company is headquartered in Oak Ridge, Tennessee, USA. Daxor has established itself as a leader in the development and commercialization of diagnostic tools that provide critical insights into blood volume and fluid management. The company’s flagship product, the BVA-100 Blood Volume Analyzer, has revolutionized the way clinicians assess and manage blood volume in patients, particularly in critical care, heart failure, and surgical settings.

Daxor’s leadership team is composed of seasoned professionals with extensive experience in the medical device and biotechnology sectors. The company’s CEO, Michael Feldschuh, has been instrumental in driving innovation and expanding the company’s market presence. Under his leadership, Daxor has focused on advancing its technology, fostering strategic partnerships, and enhancing its operational efficiency.

Core Business Segments

Blood Volume Analysis Technology

Daxor’s primary business segment revolves around its proprietary blood volume analysis technology. The company’s flagship product, the BVA-100 Blood Volume Analyzer, is a diagnostic tool that provides precise, quantitative measurements of blood volume. This technology is particularly valuable in managing conditions such as heart failure, sepsis, and critical care scenarios where accurate fluid management is crucial.

Key Products and Services:

  • BVA-100 Blood Volume Analyzer: A state-of-the-art diagnostic device that measures blood volume with unparalleled accuracy.
  • Blood Volume Kits: Single-use kits designed for use with the BVA-100 analyzer, enabling clinicians to perform blood volume measurements efficiently.
  • Clinical Support Services: Daxor offers training and support services to healthcare providers to ensure optimal utilization of its technology.

Research and Development

Daxor invests heavily in research and development to enhance its existing products and explore new applications for its technology. The company collaborates with leading medical institutions and research organizations to advance the science of blood volume analysis.

Licensing and Partnerships

In addition to its core product offerings, Daxor generates revenue through licensing agreements and strategic partnerships. These collaborations enable the company to expand its reach and integrate its technology into broader healthcare ecosystems.

Business Model

Daxor operates on a hybrid business model that combines product sales, recurring revenue from consumables, and service-based income. The company generates revenue through the sale of its BVA-100 Blood Volume Analyzer and associated blood volume kits. The single-use nature of the kits ensures a steady stream of recurring revenue as healthcare providers continue to utilize the technology.

In addition to product sales, Daxor offers training and support services to healthcare providers, further enhancing its revenue streams. The company also leverages licensing agreements and partnerships to expand its market presence and integrate its technology into new applications.

Strategic Direction

Daxor is committed to advancing its mission of improving patient outcomes through innovative blood volume analysis technology. The company’s strategic priorities include:

  • Expanding Market Penetration: Daxor aims to increase the adoption of its BVA-100 Blood Volume Analyzer in hospitals and healthcare facilities worldwide. The company is focused on educating clinicians about the benefits of its technology and demonstrating its value in improving patient care.
  • Developing New Applications: Daxor is exploring new applications for its blood volume analysis technology, including its use in oncology, nephrology, and other medical specialties.
  • Sustainability Goals: The company is committed to minimizing its environmental impact by adopting sustainable manufacturing practices and reducing waste associated with its products.
  • Investing in R&D: Daxor continues to invest in research and development to enhance its existing products and develop new innovations that address unmet medical needs.

Competitive Landscape

Daxor operates in a competitive market that includes both established medical device companies and emerging biotechnology firms. Key competitors include:

  • Edwards Lifesciences: A global leader in hemodynamic monitoring and cardiovascular devices.
  • Baxter International: A multinational healthcare company specializing in fluid management and renal care.
  • Abbott Laboratories: A diversified healthcare company with a strong presence in diagnostic and medical device markets.

Despite the competition, Daxor differentiates itself through its proprietary blood volume analysis technology, which offers unparalleled accuracy and clinical utility.

Risk Factors

Daxor faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company’s revenue is heavily reliant on the adoption of its BVA-100 Blood Volume Analyzer and associated consumables. Any decline in demand for these products could adversely affect its financial performance.
  • Regulatory Challenges: As a medical device company, Daxor is subject to stringent regulatory requirements. Delays or failures in obtaining regulatory approvals could hinder the company’s ability to bring new products to market.
  • Supply Chain Disruptions: The company relies on a global supply chain for the production of its products. Disruptions in the supply chain could impact its ability to meet customer demand.
  • Competition: The medical device market is highly competitive, and Daxor faces the risk of losing market share to competitors with larger resources and broader product portfolios.

Recent Developments

Daxor has made significant strides in advancing its technology and expanding its market presence. Recent developments include:

  • Product Innovations: The company has introduced enhancements to its BVA-100 Blood Volume Analyzer, improving its accuracy and ease of use.
  • Strategic Partnerships: Daxor has entered into collaborations with leading healthcare institutions to promote the adoption of its technology and explore new applications.
  • Global Expansion: The company has expanded its presence in international markets, targeting regions with high demand for advanced diagnostic tools.
  • COVID-19 Impact: The global pandemic highlighted the importance of accurate fluid management in critically ill patients, driving increased interest in Daxor’s technology.

Investment Considerations

Strengths:

  • Proprietary technology with proven clinical utility.
  • Recurring revenue model driven by consumables.
  • Strong focus on research and development.
  • Experienced leadership team.

Risks:

  • Dependence on a single product line.
  • Exposure to regulatory and competitive pressures.
  • Potential supply chain disruptions.

Conclusion

Daxor Corporation is a leader in blood volume analysis technology, offering innovative solutions that improve patient outcomes and enhance clinical decision-making. With a strong focus on research and development, strategic partnerships, and market expansion, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with market dependence, regulatory challenges, and competition. Overall, Daxor’s unique value proposition and commitment to innovation make it a compelling player in the medical device industry.